Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2001;32:2370-2375
doi: 10.1161/hs1001.096057
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Araki, E.
Right arrow Articles by Iadecola, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Araki, E.
Right arrow Articles by Iadecola, C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Animal models of human disease
Right arrow Ischemic biology - basic studies
Right arrow Other Stroke Treatment - Medical

(Stroke. 2001;32:2370.)
© 2001 American Heart Association, Inc.


Original Contributions

Cyclooxygenase-2 Inhibitor NS-398 Protects Neuronal Cultures From Lipopolysaccharide-Induced Neurotoxicity

Eiichi Araki, MD, PhD; Colleen Forster, BS; Janet M. Dubinsky, PhD; M. Elizabeth Ross, MD, PhD Costantino Iadecola, MD

From the Center for Clinical and Molecular Neurobiology (E.A., C.F., M.E.R., C.I.), Department of Neurology, and the Department of Neuroscience (J.M.D., M.E.R., C.I.), University of Minnesota, Minneapolis.

Correspondence to C. Iadecola, MD, Department of Neurology, University of Minnesota, Box 295 UMHC, 420 Delaware St SE, Minneapolis, MN 55455. E-mail iadec001{at}tc.umn.edu

Background and Purpose— The prostanoid-synthesizing enzyme cyclooxygenase (COX)-2 is markedly upregulated after cerebral ischemia and may participate in the mechanisms by which postischemic inflammation contributes to the late stages of ischemic brain injury. In the present study, we sought to provide additional evidence for a role of COX-2 in the mechanisms of neurotoxicity associated with inflammation.

Methods— Nine-day-old neuronal-glial cultures, prepared from the cerebral cortex of newborn C57BL/6J mice, were exposed to lipopolysaccharide (LPS), a potent proinflammatory agent. The contribution of COX-2 was investigated by using the COX-2 inhibitor NS-398.

Results— LPS produced a dose-dependent (0.001 to 10 µg/mL) and selective neuronal death that was well developed 72 hours after treatment. The effect was associated with a marked increase in the concentration of the COX reaction product prostaglandin E2 (PGE2) and of the cytokine tumor necrosis factor-{alpha} (TNF-{alpha}). NS-398 (10 µmol/L) blocked the PGE2 increase, attenuated the TNF-{alpha} increase, and prevented the neuronal death produced by LPS. TNF-{alpha}-blocking antibodies attenuated LPS-induced neuronal death, but the protection was less pronounced than that afforded by NS-398. LPS failed to elevate PGE2 or to produce cell death in neuron-enriched cultures, suggesting that glial cells are required for these effects.

Conclusions— COX-2, in part through TNF-{alpha}-related mechanisms, contributes to LPS-induced neuronal death. The data support the hypothesis that COX-2, in addition to its role in glutamate excitotoxicity, participates in the cytotoxicity associated with inflammation.


Key Words: cerebral ischemia • cytokines • inflammation • lipopolysaccharides • neurons • mice




This article has been cited by other articles:


Home page
IOVSHome page
N. N. Osborne, G.-Y. Li, D. Ji, B. L. Andrade da Costa, R. J. Fawcett, K. D. Kang, and K. D. Rittenhouse
Expression of Prostaglandin PGE2 Receptors under Conditions of Aging and Stress and the Protective Effect of the EP2 Agonist Butaprost on Retinal Ischemia
Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3238 - 3248.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T. S. Kern, C. M. Miller, Y. Du, L. Zheng, S. Mohr, S. L. Ball, M. Kim, J. A. Jamison, and D. P. Bingaman
Topical Administration of Nepafenac Inhibits Diabetes-Induced Retinal Microvascular Disease and Underlying Abnormalities of Retinal Metabolism and Physiology
Diabetes, February 1, 2007; 56(2): 373 - 379.
[Abstract] [Full Text] [PDF]


Home page
NeuroscientistHome page
N. Sang and C. Chen
Lipid Signaling and Synaptic Plasticity
Neuroscientist, October 1, 2006; 12(5): 425 - 434.
[Abstract] [PDF]


Home page
FASEB J.Home page
Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman
Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats
FASEB J, June 1, 2006; 20(8): 1162 - 1175.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
V. Mollace, C. Muscoli, E. Masini, S. Cuzzocrea, and D. Salvemini
Modulation of Prostaglandin Biosynthesis by Nitric Oxide and Nitric Oxide Donors
Pharmacol. Rev., June 1, 2005; 57(2): 217 - 252.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. Iadecola and P. B. Gorelick
The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets
Stroke, February 1, 2005; 36(2): 182 - 185.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. C. Li, B. W. Row, E. Gozal, L. Kheirandish, Q. Fan, K. R. Brittian, S. Z. Guo, L. R. Sachleben Jr., and D. Gozal
Cyclooxygenase 2 and Intermittent Hypoxia-induced Spatial Deficits in the Rat
Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 469 - 475.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S.-H. Choi, E. H. Joe, S. U. Kim, and B. K. Jin
Thrombin-Induced Microglial Activation Produces Degeneration of Nigral Dopaminergic Neurons In Vivo
J. Neurosci., July 2, 2003; 23(13): 5877 - 5886.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. C. Salzberg-Brenhouse, E.-Y. Chen, D. F. Emerich, S. Baldwin, K. Hogeland, S. Ranelli, D. Lafreniere, B. Perdomo, L. Novak, T. Kladis, et al.
Inhibitors of Cyclooxygenase-2, but Not Cyclooxygenase-1 Provide Structural and Functional Protection against Quinolinic Acid-Induced Neurodegeneration
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 218 - 228.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Liu, L. Qin, G. Li, W. Zhang, L. An, B. Liu, and J.-S. Hong
Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 212 - 218.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
H.-M. Gao, J.-S. Hong, W. Zhang, and B. Liu
Synergistic Dopaminergic Neurotoxicity of the Pesticide Rotenone and Inflammogen Lipopolysaccharide: Relevance to the Etiology of Parkinson's Disease
J. Neurosci., February 15, 2003; 23(4): 1228 - 1236.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. Liu and J.-S. Hong
Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 1 - 7.
[Abstract] [Full Text] [PDF]